NYQ · Drug Manufacturers - Specialty & Generic

Emergent BioSolutions Inc. (EBS) Stock

$7.06 +3.67% NYQ: EBS Healthcare

Valuation

MetricValue
Price$7.06
Market Cap$364.27M
P/E Ratio-1.84
P/B Ratio0.96
P/S Ratio0.42
EPS (TTM)$0.93
52-Week High$14.06
52-Week Low$4.36
Dividend Yield0.00%

Financials & Margins

MetricValue
ROE-35.91%
ROA-15.83%
ROCE-5.47%
Gross Margin14.80%
Operating Margin14.80%
Net Margin-22.96%
Debt/Equity1.70
Current Ratio5.02

Annual Financials (USD)

Metric20212022202320242025
Revenue$1.8B$1.1B$1.0B$1.0B$743.0M
Operating Profit$341.0M$-170.0M$-726.0M$-109.0M$110.0M
Net Profit$220.0M$-212.0M$-760.0M$-191.0M$53.0M
EPS$4.06$-4.22$-14.85$-3.60$0.93
Op Margin19.3%-15.2%-69.2%-10.4%14.8%

Balance Sheet (USD)

Metric20212022202320242025
Total Assets$3.0B$3.2B$1.8B$1.4B$1.3B
Total Liabilities$1.3B$1.8B$1.2B$907.0M$796.0M
Cash$576.0M$643.0M$112.0M$100.0M$205.0M
Borrowings$871.0M$1.4B$860.0M$676.0M$572.0M

Latest News

Emergent Gets $52.7 Million Contract Modification From US Government MT Newswires · Jun 29, 2026 Emergent BioSolutions Secures Contract Modification Valued at Approximately $52.7 Million for ACAM2000® (Smallpox and Mpox (Vaccinia) Vaccine, Live) from the U.S. Government GlobeNewswire · Jun 29, 2026 Emergent BioSolutions Supports Victoria’s Voice Foundation’s National Naloxone Awareness Day to Help Save Lives from Opioid Overdose GlobeNewswire · Jun 4, 2026 Emergent BioSolutions Wins $64.5 Million US Government Contract Modification for BAT MT Newswires · May 28, 2026 Emergent BioSolutions Receives $64.5 Million Contract Modification for BAT® [Botulism Antitoxin Heptavalent (A, B, C, D, E, F, G) – (Equine)] to Support U.S. Biodefense Strategy GlobeNewswire · May 28, 2026

Cash Flow (USD)

Metric20212022202320242025
Operating Cash Flow$321.0M$-34.0M$-206.0M$59.0M$171.0M
Investing Cash Flow$-450.0M$-497.0M$161.0M$102.0M$56.0M
Financing Cash Flow$-105.0M$-83.0M$-1.0M$-1.0M$-26.0M
Net Cash Flow$-45.0M$66.0M$-531.0M$-6.0M$104.0M
Free Cash Flow$96.0M$-150.0M$-258.0M$36.0M$157.0M

Valuation & Return Ratios

MetricValue
PEG Ratio-0.10
EV / EBITDA-32.43
FCF Yield26.30%
Quick Ratio2.95
Interest Coverage-1.07
Return 1Y-2.09%
Return 3Y2.32%
Return 5Y-87.36%

Ownership

Insiders Held3.85%
Institutions Held86.92%
Institutions Float Held90.40%
Institutional HolderSharesReport Date
Blackrock Inc.4,341,4622026-03-31
State Street Corporation2,849,7012026-03-31
Dimensional Fund Advisors LP2,757,1582026-03-31
American Century Companies Inc2,425,7222026-03-31
Vanguard Capital Management LLC2,257,9952026-03-31

Peer Comparison

TickerPriceChangeP/EMarket CapDiv Yield
AQSTAquestive Therapeutics, Inc. $4.78 +0.42% -7.11 $599.73M 0.00%
CMPSCOMPASS Pathways plc $13.31 -0.60% -6.19 $1.28B 0.00%
CRVSCorvus Pharmaceuticals, Inc. $10.52 +3.04% -17.03 $884.63M 0.00%
ESPR $3.18 +0.00% -131.40 $661.15M 0.00%
OLMAOlema Pharmaceuticals, Inc. $7.82 +0.00% -3.81 $683.06M 0.00%

About Emergent BioSolutions Inc.

Emergent BioSolutions Inc. is led by CEO Joseph C. Papa Jr., employs 900 people, headquartered in US, publicly traded since 2006.

Emergent BioSolutions Inc. (EBS) stock trades at $7.06 with a market capitalization of $364.27M. The stock is valued at a price-to-earnings (P/E) ratio of -1.84, price-to-book of 0.96, price-to-sales of 0.42. Over the past 52 weeks the stock has ranged between $4.36 and $14.06, and currently trades 49.8% below its 52-week high.

On profitability, Emergent BioSolutions Inc. generates a return on equity (ROE) of -35.91%, return on capital employed of -5.47%, an operating margin of 14.80%, a net profit margin of -22.96%.

Related Healthcare Stocks

LLY Eli Lilly and Company $1179.27 +0.83% JNJ Johnson & Johnson $261.44 +1.93% ABBV AbbVie Inc. $276.47 +1.49% MRK Merck & Company, Inc. Common Stock (new) $145.60 +2.26% UNH UnitedHealth Group Incorporated Common Stock (DE) $379.30 +2.25% NVS Novartis AG $143.75 +0.45% AZN AstraZeneca PLC $159.20 +0.26% TMO Thermo Fisher Scientific Inc $658.02 +0.93% AMGN Amgen Inc. $414.87 +1.82% GILD Gilead Sciences, Inc. $151.17 +2.77% ABT Abbott Laboratories $99.60 +1.13% NVO Novo Nordisk A/S $38.64 +1.20%

Popular Stocks

Apple (AAPL)Microsoft (MSFT)NVIDIA (NVDA)Alphabet (GOOGL)Amazon (AMZN)Meta (META)Tesla (TSLA)Broadcom (AVGO)JPMorgan (JPM)Visa (V)

Screens featuring this stock

High ROE Healthcare StocksLow P/E Healthcare StocksHigh Net Margin Healthcare StocksDividend Healthcare StocksLow Debt Healthcare StocksAll stock screens
Run Stock Screener Investing Guides